CVS Health Analyst Price Targets - Benzinga

CVS Health Corp

CVSNYSE

Trade with Public

Trade with Public

$86.46

1.261.48%

Últ. Act.: Oct 2, 7:59 PM

$86.93

1.732.04%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Opciones Informe de acciones

CVS Health Analyst Price Targets - Benzinga

CVS Health Analyst Price Targets

Wall Street analyst price targets and consensus rating for CVS Health (CVS).

Price Target Range — 8 Quarters

Analyst Consensus — 20 Analysts

20Buy

Consensus RatingBuy# Analysts20Avg. Consensus PT$104Upside to Avg. PT+19.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 3, 2026	UBS	Kevin Caliendo	PT Cut	Buy	$126→$118
Aug 19, 2026	Argus Research	Steve Silver	PT Raise	Buy	$104→$114
Aug 12, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$111→$118
Aug 6, 2026	UBS	Kevin Caliendo	PT Raise	Buy	$122→$126
Aug 6, 2026	Evercore ISI Group	Elizabeth Anderson	PT Cut	Outperform	$130→$125
Aug 6, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$106→$108
Jul 24, 2026	UBS	Kevin Caliendo	PT Raise	Buy	$115→$122
Jul 14, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$108→$118
Jul 13, 2026	Wells Fargo	Stephen Baxter	PT Raise	Overweight	$103→$123
Jul 9, 2026	RBC Capital	Ben Hendrix	PT Raise	Outperform	$107→$113
Jul 7, 2026	Cantor Fitzgerald	Sarah James	PT Raise	Overweight	$100→$110
Jun 23, 2026	B of A Securities	Allen Lutz	PT Raise	Buy	$100→$110
Jun 8, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$110→$115
Jun 4, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$106→$111
Jun 1, 2026	Truist Securities	David Macdonald	PT Raise	Buy	$102→$108
May 26, 2026	Barclays	Andrew Mok	PT Raise	Overweight	$101→$106
May 20, 2026	Mizuho	Ann Hynes	PT Raise	Outperform	$102→$110
May 14, 2026	Morgan Stanley	Erin Wright	PT Raise	Overweight	$93→$106
May 13, 2026	Bernstein	Lance Wilkes	PT Raise	Outperform	$94→$106
May 12, 2026	JP Morgan	Lisa Gill	PT Raise	Overweight	$101→$111

More with Benzinga EdgeGet Access

Analyst Ratings News

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

Analysts review high-yield healthcare stocks CVS, Viatris and Medtronic, citing ratings, price targets, dividend yields and recent company news.

Avi Kapoor

PRO
UBS Maintains Buy on CVS Health, Lowers Price Target to $118

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and lowers the price target from $126 to $118.

Benzinga Newsdesk

PRO
Argus Research Maintains Buy on CVS Health, Raises Price Target to $114

Argus Research analyst Steve Silver maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $104 to $114.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on CVS Health, Raises Price Target to $118

JP Morgan analyst Lisa Gill maintains CVS Health (NYSE:CVS) with a Overweight and raises the price target from $111 to $118.

Benzinga Newsdesk

PRO
UBS Maintains Buy on CVS Health, Raises Price Target to $126

UBS analyst Kevin Caliendo maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $122 to $126.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on CVS Health, Lowers Price Target to $125

Evercore ISI Group analyst Elizabeth Anderson maintains CVS Health (NYSE:CVS) with a Outperform and lowers the price target from $130 to $125.

Benzinga Newsdesk